Hartwig Medical Database
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- cfDNA
- DNA
- Education
- End of Treatment
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Innovation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Re-use data
- Research
- Scientific publications
- Uncategorized
- Whole genome sequencing
- Working in the cloud
United in Unique – every individual story is unique
On World Cancer Day, attention is drawn worldwide to the impact of this disease This year’s theme, United in Unique, highlights the fact …
Whole genome sequencing: the future of molecular diagnostics in gynecological cancer?
To mark Gynecological Oncology Awareness Month, we spoke with oncologist Eelke Gort about the role of molecular diagnostics in these …
Without structured real world data, it remains guesswork who truly benefits
The decision by the Dutch National Health Care Institute (Zorginstituut Nederland, ZiNL) to reassess the reimbursement of expensive medicines after …
Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed
Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough …
First time linking Hartwig Medical Database with the Netherlands Cancer Registry for AYA Patients
This July, the first data transfer was completed between the Netherlands Cancer Registry (NKR) and the Hartwig Medical Database for …
Clinical Trials Day and the importance of structurally recording treatment outcomes
Today, on Clinical Trials Day (May 20), we reflect on the importance of clinical research. For Hartwig, it’s a opportunity …
The viral landscape in metastatic solid cancers
Researchers from Norwegian University of Science and Technology and colleagues have recently systematically catalogued the presence of viral DNA (and …
Ten years of Hartwig Medical Foundation: a retrospect and a glimpse of the future
In its first decade, Hartwig Medical Foundation has made significant progress towards its goal of providing access to all diagnostic …
Clinical Cancer Genomics 2025: a cheerful boost for this rapidly emerging field
The atmosphere is buzzing, the excitement is almost tangible. This first Clinical Cancer Genomics Congress feels like an event that …
The Importance of Analyzing the DNA of Rare Tumors
One in four patients has a cancer type that is considered rare, meaning it occurs in fewer than six out …
To study rare cancers, collaboration is key
In honor of Rare Disease Day on February 28th, we spoke with Professor Stefan Fröhling about his research on rare …
Healthcare providers share insights about GENAYA for young adult cancer patients
In a series of short videos, our specialists share their insights on the GENAYA project. They explain what GENAYA is, …
Blogs
Medicines Policy must be based on real world data
The recent decision by the National Health Care Institute to re-evaluate expensive cancer medicines in real-world practice is a logical …
Read more
Cancer, a rare disease?
It may come as a surprise to many on this International Rare Disease Day (February 28), that a significant number …
Read more
Just one WGS test is enough to reveal everything you need to know to provide a patient with metastatic cancer with targeted treatment, be it a registered therapy or part of a research trial.